 |
2021 | The preloaded hydrophilic aspheric intraocular lens P-PCF60/A obtained the Class III medical device registration certificate from the NMPA (National Medical Products Administration). |
|
2021 | The intraocular lens products PCF60/L and PCF60/AL, suitable for a wider range of patients especially those with high myopia and high hyperopia, obtained the Class III medical device registration certificate from the NMPA. |
|
2021 | The hydrophobic aspheric toric intraocular lens obtained the CE certificate from the European Union. |
|
2021 | The porcine fibrin sealant product obtained the drug registration certificate from the NMPA. |
|
2021 | The moxifloxacin hydrochloride eye drops obtained the drug registration certificate from the NMPA. |
|
2021 | The hydrophobic modular aspheric intraocular lens obtained the CE certificate from the European Union. |
|
2020 | HYALUMATRIX, the third-generation hyaluronic acid dermal filler of Haohai Biological Technology obtained the Class III medical device registration certificate from the NMPA. |
|
2019 | Optimum Infinite, the new generation high oxygen permeable contact lens material developed by our subsidiary Contamac, received FDA approval. |
|
2019 | The subsidiary of Haohai Biological Technology, Henan Universe IOL, completed the registration change for the hydrophilic foldable intraocular lens product, adding an aspheric optical design, making it the first domestic hydrophilic aspherical foldable intraocular lens product. |
|
2016 | Janlane, our second-generation hyaluronic acid dermal filler obtained the Class III medical device registration certificate from the NMPA. |
|
2016 | Obtained CFDA Class III medical device registration certificate for Survisc which was a new-generation OVD product with high concentration |
|
2016 | Obtained CFDA Class III medical device registration certificate for second-generation HA dermal filler product, Janlane. |
|
2014 |
Obtained CFDA Class III medical device registration certificate for our lubricant eye drop product which was the only chitosan-based Class III medical device in China for eye protection. |
|
2013 |
Obtained CFDA Class III medical device registration certificate for Matrifill® which was the first mono-phase cross-linked sodium hyaluronate gel approved by CFDA. |
|
2013 |
Obtained CFDA Class III medical device registration certificate for our chitosan orthopedics intra-articular injection, which was the only Class III medical device CFDA registration certificate for orthopedics intra-articular injection in China. |
|
2009 |
Proprietary medical chitosan technology was awarded the Second Prize for the National Science and Technology Progress Award. |
|
2002 |
rhEGF was awarded the Second Price for National Science and Technology Progress Award. |
|
2001 |
Developed and obtained CFDA Class I new drug registration certificate for our rhEGF products, which were the first approved rhEGF products in the world. |
|
1997 |
Developed the first generation chitosan, which we believe was the first patented medical chitosan product for use in human body in the world. |
Milestone